Gov. Gavin Newsom said Thursday that California will begin selling affordable insulin under its own label on Jan. 1, nearly three years after he first announced a partnership to sell state-branded generic drugs at lower prices.

But California won’t be the only state making lower-cost insulin available. The nonprofit Civica said it will also distribute its economical diabetes medication to pharmacies nationwide. California began partnering with Civica in 2023 for its “CalRx” brand of insulin and put $50 million toward its development, the company said.

Starting in the new year, insulin pens will be available at a recommended price of $11 per pen, or a maximum of $55 for a five-pack, Civica said.